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Abstract
The necessity of predictive models in the drug
discovery industry cannot be understated.
With the sheer volume of potentially useful
compounds that are considered for use, it is be-
coming increasingly computationally difficult to
investigate the overlapping interactions between
drugs. Understanding this is also important to
the layperson who needs to know what they can
and cannot mix, especially for those who use
recreational drugs - which do not have the same
rigorous warnings as prescription drugs. With-
out access to deterministic, experimental results
for every drug combination, other methods are
necessary to bridge this knowledge gap. Ideally,
such a method would require minimal inputs,
have high accuracy, and be computationally
feasible. We have not come across a model that
meets all these criteria. To this end, we propose
a minimal-input multi-layer perceptron that
predicts the interactions between two drugs.
This model has a great advantage of requiring
no structural knowledge of the molecules in
question, and instead only uses experimentally
accessible chemical and physical properties
- 20 per compound in total. Using a set of
known drug-drug interactions, and associated
properties of the drugs involved, we trained our
model on a dataset of about 650, 000 entries.
We report an accuracy of 0.968 on unseen
samples of interactions between drugs on which
the model was trained, and an accuracy of
0.942 on unseen samples of interactions between
unseen drugs. We believe this to be a promising
and highly extensible model that has potential
for high generalized predictive accuracy with
further tuning.
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1 Introduction
With the rapid technological advances in the
drug discovery process as well as the prevalence
of increasingly-many drugs in our lives, under-
standing the ways in which drugs affect one an-
other in the body is a pressing problem. Not
only do we need to delineate individual effects
of chemicals in the body, we must be able to
identify the potential for interaction in order to
better design these compounds. Exhaustively
testing every drug-drug combination is both cost
and time-prohibitive due to the sheer volume
of compounds to be tested, making optimized
methods necessary to perform proper analysis
[3]. A practical approach for identifying po-
tential drug interactions and assessing associ-
ated risks has emerged in recent years with the
development of predictive pharmacological net-
works [1]. The applications of such methods are
far reaching in both the process of drug discov-
ery, as well as the societal good that would come
with easy, dynamic access to tools that allow
laypeople to better control their health. The
prevalence of the use of recreational drugs sees
many drug-related ailments coming as a result of
mixing drugs that should not be mixed. As such,
developing accessible, fast models to determine
these interactions is of great importance to our
society [3]. In this paper, we propose the use of
machine learning methods and known drug-drug
interactions to predict these interactions in un-
known drug pairings, as well as drugs on which
a model has not been trained.
One of the largest barriers to predicting drug-
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drug interactions is the complexity of factors as-
sociated with that interaction. As such, many
deterministic or exhaustive methods fail the test
of feasibility due to their necessary computa-
tional complexity. Even such a problem as codi-
fying the molecular structure of a chemical leads
to a great complexity of information to be pro-
cessed, with this processing being non-trivial of
its own merit. Therefore, any strategy to predict
these interactions reasonably and at scale needs
to be able to do so on a minimal set of param-
eters, with limited computational complexity.
Our model fits these requirements given each
drug molecule is parameterized by 20 floating-
point values, and all the necessary computation
consists of matrix operations that are hardware-
accelerated on modern computers. This leads to
a model which, on an average consumer laptop
processor (Intel R© Core i5-8259U), can predict
interactions for over 10,000 drug pairs per sec-
ond - with ≈ 0.968 accuracy.
This model determines the binary condition of
interactivity, rather than categorizing the type
or location of interaction between two drugs.
The implementation of the latter is, however, ex-
pected to progress naturally from the presented
model, and would only require superficial adjust-
ments. The reason for using a less specific model
in this paper is two-fold: the limited accessibil-
ity of a dataset that characterizes the location
and types of interactions, as well as the amount
of time allotted for completion of this project.
We, however, do not feel that this is a weakness
or limitation of the model.
The drug-drug interaction dataset used in this
paper was provided by The Science and Engi-
neering of Emerging Systems Lab [2], who col-
lected their data from DrugBank. The molecu-
lar properties of each drug were obtained from
PubChem [4], a database maintained by the Na-
tional Centre for Biotechnology Information.
2 Materials & Methods
The primary dataset used in this paper [2], is a
line-separated compilation of lists of drugs that
are known to interact with one another. There
are approximately 1, 200 unique species docu-
mented, and about 225, 000 individual drug-
drug interactions. Certain parts of the dataset
were unusable, as they specified macromolecule-
drug interactions, and we are only interested
in small-molecule drugs. Additionally, certain
compounds did not have entries in [4] that could
be programmatically downloaded and processed,
so those interactions were discarded. This left
about 190, 000 drug-drug interactions for the
training, validation, and testing of the model.
A larger and more generalized set would do well
to help the model train to determine the impor-
tant factors in a drug-drug interaction. As such,
several data augmentation techniques were per-
formed on the set in order to increase its size,
whilst not perverting the accuracy or validity of
its information.
First, given we only had records of drug-drug
interactions, we needed to generate a set of drug-
drug non-interactions. Given that this dataset
lists every subset of the drugs that do interact, a
list of non-interacting drugs could be generated
by permuting two drugs in the set, and check-
ing for their inclusion in the original dataset.
This doubled the size of the original dataset -
although it should be noted that doubling was
chosen to keep the training categories evenly dis-
tributed. This improves training performance
and avoids the necessity for weighting the train-
ing rates per category. Next, each 2-tuple of
interacting drugs was reversed and added back
into the list, again doubling the dataset. The or-
der in which the two drugs are fed into the model
should be independent of their interaction, and
as such it should be trained to find an interaction
between two drugs, regardless of which is first in
the list. This brought the size of the dataset up
to approximately 760, 000 drug pairs. This set
was then shuffled in order to prevent the model
from learning any patterns present in the origi-
nal presentation of the data. Of this full set, 10%
is set aside for validation during training, and a
further 10% composes the testing set. These are
chosen randomly, although for the purposes of
comparing models, the generator seed was fixed
in order to allow comparable statistics.
Once the interaction set was processed, infor-
mation of the individual compounds needed to
be associated with each drug in an interaction.
This data was obtained from [4], and certain
attributes were extracted and assigned to the
interacting molecules to be fed into the model.
The full list of extracted properties can be see
in Table 1. Note that although these are mostly
integer-valued parameters, for the purposes of
computation they are treated as floating-point
values.
The neural network is a feed-forward network,
meaning propagation only goes in the forward
direction. Specifically, it is a multi-layer percep-
tron, with numerous hidden layers. Given the
assumed non-linearity of this problem, at least
several latent layers were necessary to predict in-
teractions with any degree of accuracy. Each la-
tent layer is either simply a fully-connected (FC)
layer, a dropout layer, or a batch normalization
(BN) layer. The network follows a diamond-
like structure for the number of nodes per layer,
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Table 1: Chemical Parameters for Input into
Model
Parameter Type
# of C atoms Integer
# of H atoms Integer
# of N atoms Integer
# of O atoms Integer
# of F atoms Integer
# of S atoms Integer
# of P atoms Integer
# of Cl atoms Integer
# of I atoms Integer
# of Br atoms Integer
Log (P) Decimal
# of H-bond acceptors Integer
# of H-bond donors Integer
# of rotatable bonds Integer
# of heavy atoms Integer
Complexity (Bertz formula) Integer
# of def. atom stereocentres Integer
# of undef. atom stereocentres Integer
# of def. bond stereocentres Integer
# of undef. bond stereocentres Integer
starting with 256, increasing over several layers
to 512, and then decreasing over several layers
to 128 before the final output. Every FC layer is
proceeded by a BN layer. Table 2 breaks down
each layer of the network. Additionally, layers
are grouped together to create a ‘super-layer’
structure composed of two identically sized sets
of an FC and BN layer, all followed by a dropout
layer. The purpose of these dropout layers is to
prevent the model from being able to ‘memo-
rize’ the training data to artificially increase its
training accuracy. Both the first and second la-
tent layers as well as the last latent layer lack a
dropout layer proceeding them to prevent early-
stage data loss and highly variable classification
respectively. The FC layers use rectified linear
units (ReLUs) for activation, while the output
layer uses a sigmoid function. Adam was used
as the optimizer, with parameters left as default.
All dropout layers use a drop rate of 0.3, and
the total number of trainable parameters in the
model is 744, 449. Various numbers of epochs
were used for training in order to identify the
optimal value, and batch sizes between 32 and
256 were tested for the same purpose.
After training, the model is evaluated on the
testing set to quantify how well it has learned
- i.e. its generalizability. As well, the model
is tested on the interactions (or lack thereof) of
Table 2: Layers Composing Model
Type Activation Output Parameters
Input 40
FC ReLU 256 11520
BN 256 1024
FC ReLU 256 65792
BN 256 1024
FC ReLU 512 131584
BN 512 2048
FC ReLU 512 262656
BN 512 2048
Dropout 512
FC ReLU 256 131328
BN 256 1024
FC ReLU 256 65792
BN 256 1024
Dropout 256
FC ReLU 128 32896
BN 128 512
FC ReLU 128 16512
BN 128 512
Dropout 128
FC ReLU 128 16512
BN 128 512
FC Sigmiod 1 129
drugs upon which it has not been trained - a
further test of how well this model actually pre-
dicts drug-drug interactions. The data for this
last test is obtained from [4].
3 Results
In this project, the architecture of the network
remained fundamentally unchanged throughout
testing after being determined from early tests
on several variants. These early tests were fo-
cused on the number of FC layers in each super-
layer, as well as the number of super-layers (i.e.
the depth of the network). As well, it was deter-
mined how many FC layers were to be included
before the first super-layer, and after the final.
As can be seen in Table 2, it was found that
the model performed optimally (in terms of the
validation accuracy after 100 epochs) with two
FC layers, then three super-layers, then a sin-
gle FC layer before the output. In whole, ev-
ery combination of 1 to 3 FC layers before the
super-layers, 1 to 5 super-layers, and 1 to 3 FC
layers after the super-layers was tested. As well,
different numbers of neurons in each layer and
super-layer were tested, all with the diamond
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pattern described earlier. It was found that the
sizes 256, 512, 256, 128, 128 performed best of
the tested hyperparameters.
The final, best performing model used the ar-
chitecture mentioned previously, with uniform
dropout rates of 0.3, a batch size of 64, and
trained over 65 epochs. The training accuracy
curve can be seen in Figure 1. Of particular
note is how well the validation accuracy mimics
the training accuracy. When tested on a set of
unseen interactions for known drugs, the model
scored a binary accuracy of 0.968, lining up very
closely with the validation accuracy at epoch 65
of 0.965. When tested on a set of unseen interac-
tions between unknown drugs, the model scored
a binary accuracy of 0.942. This small drop in
accuracy is expected due to the generalization
of the data being tested on. A confusion matrix
for the can be seen in Figure 2. The model itself
is relatively small, with the whole architecture
and learned weights coming out to about 9MB
in size.
Figure 1: A plot of the training and valida-
tion accuracy over 65 epochs for a model trained
on approximately 650, 000 samples with a batch
size of 64. Training took about 120 minutes.
The testing accuracy for this model is 0.965 on
unseen interactions, and 0.942 on unseen drugs.
4 Discussion
In training a slew of models based on the de-
termined architecture, we were able to tune the
hyperparameters - including the dropout rate,
output size of FC layers, activation functions
and learning rate - and ascertain the best per-
formance from our chosen architecture. Al-
though simplistic, the simplicity is what makes
the model as efficient as it is. To train over 65
epochs on about 650, 000 interactions takes just
under two hours on two Nvidia R© P100 GPUs -
Figure 2: A confusion matrix showing the cor-
rect and incorrect predictions of drug-drug in-
teractions over the seen drugs testing set. The
column-wise contrast of colour intensity repre-
sent the statistical power and specificity of 0.937
and 0.996 respectively.
quite a short time in this field. This makes the
model highly extensible to much larger datasets,
while staying within reasonable training times,
even without optimal hardware. The potential
for models such as this to find a purpose out-
side dedicated research laboratories hinges on
their efficiency. To be used in a consumer-facing
application that predicts drug interactions, this
model needs to be accessible outside of the field -
in terms of necessary computational power, ease
of use, and ease of access to necessary informa-
tion. We believe that our model meets these
criteria.
Of most important note from our results is the
final accuracies this model was able to achieve
for both known and unknown drugs. The latter
of the two was lower, at only 0.942, but this
is to be expected with the generalization of the
model. The fact that the drop in accuracy was so
small (just over 0.02) is a great encouragement
to the efficacy of this model at predicting drug-
drug interactions. It seems to have been able to
extract some of the most important information
that determines whether two drugs will interact,
as it does so without having seen those drugs in
its training.
The importance of models as the one we have
created here cannot be overstated. Being able
to predict drug-drug interactions is vitally im-
portant in both the commercial setting of drug
development, as well as in the context of an indi-
vidual being able to know and understand what
drugs they should and should not be able to take
together. In order for a model to address the
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needs in whatever sector, it must be able to, with
high accuracy, quickly determine from minimal
information whether two compounds will inter-
act. Where many other models working to this
end have failed previously is in this last criterion
[1, 3]. Most models require an intimate knowl-
edge of the structures of the chemicals of interest
at a minimum, and often require in addition to
that a host of other information that is not easily
accessible for any given molecule. The strength
of our minimal information requirement is that
these parameters can be experimentally deter-
mined without knowing or having to encode the
structure of the molecule, and uses very readily
available properties of compounds. This saves
not only on the burden of procuring datasets
that have all the necessary information, it re-
duces the number of necessary tests to be run on
a compound before one has the requisite amount
of necessary information to predict the interac-
tion of two drugs. This not only improves the
logistics of using such a model, it decreases the
amount of time to both train and utilize that
model and makes it more accessible in whole.
As mentioned previously, one of the primary
extensions of the model in its current state is
to switch from the binary classification of inter-
action to a categorical classification of the type
and location of interaction. We consider this
a natural extension, and preliminary tests with
small sets indicates promising results, similar
to the accuracy for binary classification. The
primary barrier to this is the procurement of
a dataset that has labelled interaction infor-
mation, but this information is available to be
created through processing raw data provided
by [4].
A further improvement is to increase the num-
ber of parameters read into the network for each
drug. While the set given provides a relatively
high degree of accuracy, the classification accu-
racy could be improved by including other, eas-
ily obtainable properties of the chemicals of in-
terest. Again, the only boundary to this is the
time it would take to compile a labelled dataset
with the requisite information.
Finally, we would like to perform sensitivity
analysis on the model. This is an endeavour
in and of itself, but doing so would allow for
an entirely new and informative purpose to the
model by correlating each input with its effect
on the model’s output. This is effectively a way
to determine which chemical properties are most
important in determining whether or not they
will interact in the body. The hope in doing
so is to further investigate where areas of re-
search should focus to best characterize and pre-
dict these interactions.
Conclusions
With available resources and sufficient drug
data, this model has potential to predict drug-
drug interactions with a high degree of accuracy.
The implications of this model are capable of
great societal benefit, in terms of pharmacoeco-
nomics and public health [3, 5]. With sufficient
accuracy, the model can reduce high develop-
ment expenses and save time by avoiding rig-
orous testing for drug-drug interactions during
drug discovery. By predicting interactions com-
putationally rather than experimentally, the ef-
ficiency of the pharmaceutical industry can be
improved [5]. As the number of drugs and chem-
icals continues to grow, along with their interac-
tions, models such as this become increasingly
important.
With recreational drug use becoming more
common, the importance of drug-drug interac-
tion prediction is exceedingly pertinent [3]. The
growing variety of both legal and illegal recre-
ational drugs raises the potential for unfore-
seen consequences related to various drug com-
binations [3]. Using the minimal-input multi-
layer perceptron network described here allows
for quick prediction with sufficient information
(which is largely readily available online) to
predict possible problematic interactions. The
availability of the model to the world of medicine
as well as the public can be far reaching in im-
proving public health.
References
[1] Aurel Cami, Shannon Manzi, Alana Arnold,
and Ben Y. Reis. Pharmacointeraction Net-
work Models Predict Unknown Drug-Drug
Interactions. PLOS ONE, 8(4):e61468, April
2013.
[2] Roger Guimerà and Marta Sales-Pardo. A
Network Inference Method for Large-Scale
Unsupervised Identification of Novel Drug-
Drug Interactions. PLoS Computational Bi-
ology, 9(12):e1003374, December 2013.
[3] Andrej Kastrin, Polonca Ferk, and Brane
Leskošek. Predicting potential drug-drug in-
teractions on topological and semantic sim-
ilarity features using statistical learning.
PLOS ONE, 13(5):e0196865, May 2018.
[4] Sunghwan Kim, Jie Chen, Tiejun Cheng,
Asta Gindulyte, Jia He, Siqian He, Qingliang
Li, Benjamin A. Shoemaker, Paul A.
Thiessen, Bo Yu, Leonid Zaslavsky, Jian
Zhang, and Evan E. Bolton. Pub-
Chem 2019 update: improved access to
5
chemical data. Nucleic Acids Research,
47(D1):D1102–D1109, 2019.
[5] Takako Takeda, Ming Hao, Tiejun Cheng,
Stephen H. Bryant, and Yanli Wang. Pre-
dicting drug–drug interactions through drug
structural similarities and interaction net-
works incorporating pharmacokinetics and
pharmacodynamics knowledge. Journal of
Cheminformatics, 9(1):16, March 2017.
6
